Unknown

Dataset Information

0

Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy.

ABSTRACT:  We perform a large-scale meta-analysis of 51 peer-reviewed 3xTg-AD mouse publications to compare Alzheimer's disease (AD) quantitative clinical outcome measures, including amyloid-? (A?), total tau, and phosphorylated tau (pTau), with cognitive performance in Morris water maze (MWM) and Novel Object Recognition (NOR). "High" levels of A? (A?40, A?42) showed significant but weak trends with cognitive decline (MWM: slope?=?0.336, R2?=?0.149, n?=?259, p?

SUBMITTER: Huber CM 

PROVIDER: S-EPMC5734131 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy.

Huber Colin M CM   Yee Connor C   May Taylor T   Dhanala Apoorva A   Mitchell Cassie S CS  

Journal of Alzheimer's disease : JAD 20180101 1

 We perform a large-scale meta-analysis of 51 peer-reviewed 3xTg-AD mouse publications to compare Alzheimer's disease (AD) quantitative clinical outcome measures, including amyloid-β (Aβ), total tau, and phosphorylated tau (pTau), with cognitive performance in Morris water maze (MWM) and Novel Object Recognition (NOR). "High" levels of Aβ (Aβ40, Aβ42) showed significant but weak trends with cognitive decline (MWM: slope = 0.336, R2 = 0.149, n = 259, p < 0.001; NOR: slope = 0.156, R2 = 0.064, n =  ...[more]

Similar Datasets

Unknown Inter-network connectivity and amyloid-beta linked to cognitive decline in preclinical Alzheimer's disease: a longitudinal cohort study.
| S-EPMC6114059 | biostudies-literature
Unknown APOE and BDNF polymorphisms moderate amyloid ?-related cognitive decline in preclinical Alzheimer's disease.
| S-EPMC4759101 | biostudies-literature
Unknown Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.
| S-EPMC5262471 | biostudies-literature
Unknown BMI1 is associated with CS8F amyloid-β and rates of cognitive decline in Alzheimer's disease.
| S-EPMC8493672 | biostudies-literature
Unknown Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease.
| S-EPMC7507636 | biostudies-literature
Unknown Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.
| S-EPMC5915512 | biostudies-literature
Unknown Widespread distribution of tauopathy in preclinical Alzheimer's disease.
| S-EPMC6422832 | biostudies-literature
Unknown Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer's disease.
| S-EPMC7775771 | biostudies-literature
Unknown The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer's disease.
| S-EPMC7423599 | biostudies-literature
Unknown NLRP3-dependent microglial training impaired the clearance of amyloid-beta and aggravated the cognitive decline in Alzheimer's disease.
| S-EPMC7555905 | biostudies-literature